Agilent (A) Q2 2025: Ignite Delivers $130M Profit Amid Tariff Headwinds and 70% PFAS Growth
Agilent’s Q2 2025 performance outpaced expectations, powered by robust segment diversity, rapid tariff mitigation, and innovation in high-growth areas like PFAS testing and CDMO services. Leadership’s Ignite transformation is now a tangible profit driver, offsetting macro and tariff pressures. Management’s measured outlook signals focus on sustainable execution and margin recovery in 2026.
Summary
- Ignite Transformation Drives Profitability: Enterprise-wide cost and pricing initiatives now offset major tariff headwinds.
- PFAS and CDMO Businesses Accelerate: High-growth segments are expanding Agilent’s long-term addressable market.
- Margin Recovery Set for 2026: Supply chain moves and pricing power position Agilent for gross margin tailwinds next year.
Performance Analysis
Agilent delivered a fourth consecutive quarter of accelerating core revenue growth, with all major geographies contributing and China leading at 10%. Growth was broad-based across end markets, with diagnostics and clinical, environmental and forensics, and food all posting mid- to high-single-digit gains. Notably, PFAS, per- and polyfluoroalkyl substances, testing surged over 70% year-over-year, now annualizing well above $100 million, and contributed 80 basis points to overall growth. The CrossLab Group (ACG), which provides consumables and services, led business segment performance with 9% revenue growth, driven by automation, consumables, and a return to growth in both on-demand and installation services.
Gross margin landed at 54.1%, pressured by 55 basis points of incremental tariff costs, yet operating margin held steady at 25.1% as Ignite transformation savings and pricing actions kicked in. The company absorbed $10 million in tariff costs in H1 and expects another $50 million in H2, but Ignite initiatives are projected to fully offset these by 2026. Operating cash flow was $221 million, with increased inventory and CapEx to support supply chain resilience and tariff mitigation. The balance sheet remains robust, with net leverage at 1.0, enabling continued capital returns and M&A optionality.
- PFAS Testing Momentum: PFAS revenue more than doubled in Europe and China, positioning Agilent to capture share in a $1 billion market by 2030.
- CDMO and NASD Growth: NASD, nucleic acid solutions division, and BioVectra, contract development and manufacturing organization, both outperformed, with NASD set for double-digit growth in H2, supported by a shift toward more commercial programs.
- Digital Orders and CrossLab Strength: Digital order volume rose 12% to $295 million, while ACG’s high attach rates and automation growth reinforce recurring revenue streams.
Despite macro and tariff volatility, Agilent’s diversified model and Ignite-driven agility are enabling both near-term resilience and long-term margin expansion potential.
Executive Commentary
"Ignite has become the backbone of our operating system, enabling faster decision-making, more scalable growth, and over $130 million of profit for fiscal year 2025. It is our institutional engine for long-term value creation."
Porek McDonald, President and CEO
"Given the impact of [tariffs], it'll be closer to flat versus year ago. If you took that out, we would still be on track for the margin expansion... So we still feel good about that cadence going forward, particularly when we talk about 2026."
Bob McMahon, Senior Vice President and CFO
Strategic Positioning
1. Ignite Operating Model as Margin Engine
Ignite, Agilent’s enterprise transformation program, is now producing tangible financial results, delivering $130 million in profit for FY25 and driving $80 million in annualized SG&A savings starting in H2. Key levers include centralized procurement, flattened management layers, and advanced pricing analytics. These actions are not only offsetting tariff costs but also positioning Agilent for sustained operating leverage as volume returns in 2026 and beyond.
2. High-Growth Segments Expanding TAM
PFAS testing and CDMO services are emerging as secular growth drivers. PFAS testing, fueled by tightening global regulations, is now a $100 million-plus annualized business for Agilent, with the company tracking over 350 regulations and deploying differentiated workflow solutions. In CDMO, NASD and BioVectra are capitalizing on demand for GLP-1s and advanced modalities, with order books providing visibility into 2026. The revenue mix in NASD is shifting toward commercial programs, supporting improved utilization and profitability.
3. China and India: Regional Engines with Tailwinds
China delivered 10% growth, aided by favorable Lunar New Year comparisons and stimulus in applied markets, while India posted high-teens growth and now hosts Agilent’s first Solutions Center. Management anticipates further upside from a second phase of China stimulus, with a robust funnel for H2 and Q4, though this is not yet embedded in guidance.
4. Innovation Pipeline and Installed Base Replacement
Recent launches such as the Seahorse XF Flex Analyzer and Infinity Lab Pro IQ Series are enhancing Agilent’s competitive positioning in cell analysis and LC-MS. The Infinity III replacement cycle is driving higher attach rates for consumables and services, with thousands of legacy systems in the funnel and a typical six- to nine-month sales cycle. GC and GCMS installed base aging is also creating a multi-year replacement opportunity, supported by new product introductions and energy-efficient systems.
5. Tariff Mitigation and Supply Chain Localization
Agilent’s Tariff Task Force, enabled by Ignite, is centralizing procurement, moving production (e.g., LC) into the US, and leveraging global sourcing to localize supply chains. These efforts are expected to fully offset gross tariff exposure by 2026, with pricing surcharges and inventory builds providing interim relief. Management’s proactive stance is a differentiator versus peers, supporting customer retention and margin stability.
Key Considerations
Agilent’s Q2 demonstrated the strategic value of a diversified portfolio, disciplined cost structure, and agile response to external shocks. The company’s ability to absorb $60 million in tariff costs in FY25 without revising EPS guidance underscores the depth of its mitigation toolkit and the growing impact of Ignite. Meanwhile, end-market exposure remains well balanced, with pharma, diagnostics, applied markets, and services each providing distinct growth and margin levers.
Key Considerations:
- Tariff Mitigation Speed: Ignite-driven procurement and supply chain moves are already offsetting 2025 tariff costs, with full mitigation expected in 2026.
- Secular Growth in PFAS and CDMO: PFAS and advanced modalities in CDMO are expanding Agilent’s total addressable market and supporting above-market growth rates.
- Installed Base Replacement Cycles: Ongoing replacement of legacy LC, GC, and GCMS systems is driving higher service and consumables attach rates, reinforcing recurring revenue.
- China and Stimulus Dynamics: China’s sequential stability and anticipated stimulus funnel provide upside, though not yet in guidance.
- Operational Resilience: Flat operating margins despite tariff headwinds reflect the effectiveness of Ignite and pricing power in a dynamic macro environment.
Risks
Tariff and geopolitical volatility remain the most immediate risk, with $50 million in H2 tariff exposure and potential for further escalation in US-EU rates. While Ignite and inventory actions mitigate near-term impact, execution risk remains around supply chain moves and pricing power. Macro uncertainty, especially in academia/government funding and pharma R&D, could pressure growth if conditions worsen. Regulatory shifts in PFAS and food testing may also create demand unpredictability.
Forward Outlook
For Q3 2025, Agilent guided to:
- Revenue of $1.645 billion to $1.675 billion, core growth of 1.7% to 3.6%.
- Non-GAAP EPS of $1.35 to $1.37, up 2.3% to 3.8% YoY.
For full-year 2025, management maintained guidance:
- Core revenue growth of 2.5% to 3.5%, with reported revenue raised by $50 million on FX tailwinds.
- Non-GAAP EPS of $5.54 to $5.61, up 4.7% to 6% YoY, fully absorbing incremental tariff costs.
Management emphasized continued discipline given macro and tariff uncertainty, with Ignite-driven mitigations supporting EPS stability and margin expansion potential in 2026. PFAS, CDMO, and installed base replacement cycles are expected to be key growth levers in the second half and beyond.
Takeaways
Agilent’s Q2 2025 underscores the company’s ability to deliver resilient growth and profitability in a volatile macro environment, with Ignite transformation and high-growth segments providing both near-term defense and long-term offense.
- Ignite Impact: Tariff mitigation, procurement centralization, and pricing analytics are now directly supporting profit and offsetting external shocks.
- Growth Engines: PFAS and CDMO businesses are scaling rapidly, providing visibility and margin tailwinds for 2026 and beyond.
- Watch Installed Base and China Stimulus: Replacement cycles and China’s next stimulus round are potential upside drivers, while execution on supply chain moves and pricing will be key to sustaining margin recovery.
Conclusion
Agilent’s Q2 results validate the strategic pivot to Ignite and the operational agility it brings. With disciplined guidance, robust end-market diversity, and clear margin recovery levers, Agilent is positioned to outperform peers as macro and tariff risks ebb in 2026.
Industry Read-Through
Agilent’s rapid tariff mitigation, supply chain localization, and pricing agility set a benchmark for life sciences and diagnostics peers facing similar geopolitical and cost pressures. The company’s ability to absorb significant tariff costs without sacrificing EPS or margin expansion plans highlights the value of proactive enterprise transformation. PFAS testing’s explosive growth and regulatory-driven demand signal a secular opportunity for analytical instrument and workflow providers, while CDMO momentum and installed base replacement cycles foreshadow multi-year tailwinds for companies with recurring revenue models and innovation pipelines. Investors should monitor how peers adapt their cost structures and supply chains in response to the evolving tariff landscape and regulatory environment.